Randomized, Open Label, Active Controlled Comparative Study to Assess Safety, Efficacy of Mometasone & Formoterol Versus Fluticasone & Formoterol Dry Powder Inhaler in Treatment of Mild to Moderate Persistent Asthma

Authors

  • Parasuramalu B G KIMS, Bangalore
  • Sathish Chandra MR BGS Global Institute of Medical Sciences, Bangalore
  • Huliraj N KIMS, Bangalore
  • Giriyanna Gowda KIMS, Bangalore
  • Gangaboraiah KIMS, Bangalore

Keywords:

Mild to moderate persistent Asthma, dry powder inhaler, safety, efficacy

Abstract

Background: This study conducted to assess and compare the safety and efficacy of Mometasone & Formoterol versus Fluticasone & Formoterol. in patients with mild to moderate persistent asthma on symptom control and rescue medication usage.

Method: The present study was conducted during March 2011 to February 2012. 120 patients were randomized in to two groups and were given Mometasone & Formoterol to group 1 and Fluticasone & Formoterol to group 2 for 12 weeks.

Result: Out of 60 patients recruited in each group 7 were lost to follow up in Fluticasone group and 4 in Mometasone group. Out of 53 patients in Fluticasone group, 11 developed adverse reactions. Whereas in Mometasone group out of 56 patients- 7 developed adverse reactions. The overall improvement in Spi- rometry parameters was better in Mometasone group com- pared to Fluticasone which was not statistically significant suggesting both were equally efficacious. There was reduction in dosage of rescue medication used from baseline to the end of 12 weeks in Mometasone group compared to Fluticasone group.

Conclusion: Both combinations were safe and equally effica- cious in treating mild to moderate persistent asthma patients.

References

Masoli M, Fabian D, Holt S, Beasley R. The global bur- den of asthma: executive summary of the GINA Dis- semination Committee report. Allergy 2004; 59(5):469- 78.

Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2- agonists and corticoster- oids. Eur Respir J 2002; 19: 182–91.

D’Urzo A. Mometasone furoate dry-powder inhaler for the control of persistent asthma. Expert Opin Pharma- cotherapy 2007;8(16):2871-84.

James Wolfe, Craig LaForce, Bruce Friedman, William Sokol, Denise Till, Giovanni Della Cioppa et al. Formeterol, 24microg bid and serious asthma exacerba- tions. Chest 2006; 129:27-38.

Andy Wardlaw, Pierre Larivee, Jorg Eller, Donald W.Cockcroft, Lisa Ghaly, Harris. Efficacy and safety of Mometasone Furoate dry powder inhaler vs Fluticasone Propionate metered dose inhaler in asthma subjects previously using Fluticasone Propionate. Ann Allergy Asthma Immunol.2004; 93:49-55.

David I Bernstein, Jacques Hebert, Amarjit Cheema, Kevin R Murphy, Ivan Cheerez- Ojeda, Carlos Edu- ardo Matiz-Bueno et al., Efficacy and onset of action of Mometasone Furoate / Formoterol and Fluticasone propionate/ Salmeterol combination treatment in sub- jects with persistent asthma. Allergy, Asthma & Clini- cal Immunology 2011; 7:21.

Neeta Kumar, Neeru Gupta, Jugal Kishore. Kuppus- wamy’s socioeconomic scale: Updating income Ranges for the Year 2012. Indian Journal of Public Health. 2012; 56(1):103-4.

Downloads

Published

2015-06-30

How to Cite

1.
Parasuramalu B G, Chandra MR S, Huliraj N, Gowda G, Gangaboraiah. Randomized, Open Label, Active Controlled Comparative Study to Assess Safety, Efficacy of Mometasone & Formoterol Versus Fluticasone & Formoterol Dry Powder Inhaler in Treatment of Mild to Moderate Persistent Asthma. Natl J Community Med [Internet]. 2015 Jun. 30 [cited 2024 Dec. 22];6(02):263-9. Available from: https://njcmindia.com/index.php/file/article/view/1177

Issue

Vol. 6 No. 02 (2015)

Section

Original Research Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.